EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Drug‐induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID‐19 in a patient under anastrozole therapy—A case report

Wolfgang Lischka, Gernot Kriegshäuser iD

Cancer Reports · 2024-04 · 7 (4)

DOI: 10.1002/cnr2.2028 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 05.04.2024. Verfasst von Wolfgang Lischka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice, Gumpoldskirchen, Austria. Hauptthemen laut MEDLINE: COVID-19, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anastrozole is a selective aromatase inhibitor used for the treatment of postmenopausal hormone‐sensitive breast cancer. The major side effects include osteoporosis, hypercholesterolemia, and musculoskeletal events, such as arthralgia and myalgia. Other adverse events are rare, including symptoms of acne, masculinization, and drug‐induced liver injury, with the latter reported in a few cases only. Case Here, we report on a patient under anastrozole therapy who developed drug‐induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method 5 weeks after a mild SARS‐CoV‐2 infection, which is, to the best of our knowledge, the first report of its kind involving anastrozole. Discontinuation of anastrozole resulted in a marked improvement of the alanine aminotransaminase, and aspartate aminotransaminase as well as normalized lactate dehydrogenase serum levels already seen after 26 days. Surprisingly, however, the cholestatic serum markers gamma‐glutamyl transpeptidase and alkaline phosphatase showed a further rise, and took another 4 weeks to drop significantly.

Conclusion

The presentation of this case is meant to alert physicians to a potential drug‐induced liver injury following mild SARS‐CoV‐2 infection in patients under anastrozole medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Chemical and Drug Induced Liver InjuryHumansAnastrozoleSARS-CoV-2Aromatase Inhibitors

Stichwörter der Autor:innen

COVID‐19anastrozolecholestaticdrug‐induced liver injuryhepatocellularupdated RUCAM

Substanzen

AnastrozoleAromatase Inhibitors

Autor:innen und Institutionen

  • Private Practice, Gumpoldskirchen, Austria.
  • Department of Medical Genetics, Yerevan State Medical University, Yerevan, Armenia.

ORCID-Profile: Gernot Kriegshäuser

Zitieren

APA

Lischka, W., & Kriegshäuser, G. (2024). Drug‐induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID‐19 in a patient under anastrozole therapy—A case report. Cancer Reports, 7(4). https://doi.org/10.1002/cnr2.2028

Vancouver

Lischka W, Kriegshäuser G. Drug‐induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID‐19 in a patient under anastrozole therapy—A case report. Cancer Reports. 2024;7(4). doi:10.1002/cnr2.2028

BibTeX
@article{Lischka2024,
  author = {Lischka, Wolfgang and Kriegshäuser, Gernot},
  title = {Drug‐induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID‐19 in a patient under anastrozole therapy—A case report},
  journal = {Cancer Reports},
  year = {2024},
  volume = {7},
  number = {4},
  doi = {10.1002/cnr2.2028}
}
Kostenlos starten →